Syngene International Ltd.
NSE: SYNGENE | BSE: 539268
₹471.35
As on 19-May-2026IST
Market cap
₹19,013 Cr
Revenue (TTM)
₹3,739 Cr
P/E Ratio
60
P/B Ratio
3.9
Div. Yield
0.3 %
Quality Score
8/10
Growth Score
6/10
Valuation Score
4/10
Momentum Score
1/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹317 Cr
-
ROE
11.2 %
-
ROCE
15.4 %
-
Industry P/E
59.42
-
EV/EBITDA
18.4
-
Debt to Equity
0
-
Book Value
₹119.9
-
EPS
₹8.9
-
Face value
10
-
Shares outstanding
403,669,147
10 Years Aggregate
CFO
₹6,774.90 Cr
EBITDA
₹6,677.20 Cr
Net Profit
₹3,848.50 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| -27.6 | 8.0 | 8.8 | -27.0 | -12.3 | -4.2 | 9.0 |
|
BSE Healthcare
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Syngene Intl
| -26.0 | 21.0 | 19.8 | -5.5 | -2.0 | 98.4 | 14.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Syngene Intl
|
471.4 | 19,012.8 | 3,738.7 | 316.7 | 12.5 | 7.5 | 60 | 3.9 |
| 2,886.5 | 23,571.5 | 1,339.4 | 356.4 | 33.2 | 23.2 | 66.2 | 14.3 | |
| 428.4 | 16,429.4 | 2,268.6 | 150.1 | 10.6 | 5.4 | 91.7 | 4.2 | |
| 766.5 | 18,987.4 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.9 | 3.7 | |
| 1,011.0 | 16,103.3 | 7,918.4 | 429.9 | 10.7 | 7.2 | 37.2 | 2.4 | |
| 1,130.9 | 20,272.6 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13 | 2.3 | |
| 1,854.5 | 21,173.9 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.6 | |
| 173.2 | 23,029.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.8 | |
| 984.5 | 16,337.5 | 1,284.3 | 134.4 | -- | 30.7 | 121.6 | 13.4 | |
| 1,620.2 | 26,242.5 | 3,373.0 | 199.0 | 12.6 | 5.9 | 123.2 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
1 min read•By Research Desk
About Syngene Intl
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services,... such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited. Read more
-
Incorporated
1993
-
Chairman
Kiran Mazumdar-Shaw
-
Managing Director
Peter Bains
-
Headquarters
Bengaluru, Karnataka
-
Website
Looking for more details about Syngene International Ltd.’s IPO? Explore our IPO Details page.
Quarterly Updates
Annual Reports
FAQs for Syngene Intl
What is the current share price of Syngene International Ltd Today?
The share price of Syngene International Ltd is ₹471.35 (NSE) and ₹471.10 (BSE) as of 19-May-2026 IST. Syngene International Ltd has given a return of -12.32% in the last 3 years.
What is the current PB & PE ratio of Syngene International Ltd?
The P/E ratio of Syngene International Ltd is 60.03 times as on 19-May-2026, a 1 premium to its peers’ median range of 59.42 times.
The P/B ratio of Syngene International Ltd is 3.93 times as on 19-May-2026, a 10 premium to its peers’ median range of 3.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
58.90
|
6.29
|
|
2024
|
55.31
|
6.73
|
|
2023
|
51.39
|
6.72
|
|
2022
|
60.44
|
7.45
|
|
2021
|
53.68
|
7.92
|
What is the 52 Week High and Low of Syngene International Ltd?
The 52-week high and low of Syngene International Ltd are Rs 728.60 and Rs 380.00 as of 19-May-2026.
What is the market cap of Syngene International Ltd?
Syngene International Ltd has a market capitalisation of ₹ 19,013 Cr as on 19-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Syngene International Ltd?
Before investing in Syngene International Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.